Insider Trading Alert - ENTA, KMG And PSEC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, June 12, 2015, 76 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $5,841,705.00.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Mellett Paul J, who is Treasurer and CFO at Enanta Pharmaceuticals, sold 7,500 shares at $42.51 on June 12, 2015. Following this transaction, the Treasurer and CFO owned 90,397 shares meaning that the stake was reduced by 7.66% with the 7,500-share transaction.

The shares most recently traded at $41.98, down $0.53, or 1.26% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 34,750
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 42,750
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 92,250

The average volume for Enanta Pharmaceuticals has been 310,900 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $794.6 million and is part of the health care sector and drugs industry. Shares are down 17.58% year-to-date as of the close of trading on Friday.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. The company has a P/E ratio of 7.0. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Enanta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

KMG Chemicals (KMG) - FREE Research Report

Hatcher David L, who is 10% Owner at KMG Chemicals, sold 1,500 shares at $28.74 on June 12, 2015. Following this transaction, the 10% Owner owned 1.9 million shares meaning that the stake was reduced by 0.08% with the 1,500-share transaction.

The shares most recently traded at $29.01, up $0.27, or 0.93% since the insider transaction. Historical insider transactions for KMG Chemicals go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 27,000
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 69,000
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 74,000

The average volume for KMG Chemicals has been 84,800 shares per day over the past 30 days. KMG Chemicals has a market cap of $337.6 million and is part of the basic materials sector and chemicals industry. Shares are up 46.8% year-to-date as of the close of trading on Friday.

KMG Chemicals, Inc., through its subsidiaries, engages in the manufacture, formulation, and distribution of specialty chemicals in the United States, Mexico, Canada, Europe, Israel, and Singapore. It operates in two segments, Electronic Chemicals and Wood Treating Chemicals. The stock currently has a dividend yield of 0.42%. The company has a P/E ratio of 43.1. Currently, there is 1 analyst who rates KMG Chemicals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KMG - FREE

TheStreet Quant Ratings rates KMG Chemicals as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full KMG Chemicals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Prospect Capital Corporation (PSEC) - FREE Research Report

Barry John F, who is Chief Executive Officer at Prospect Capital Corporation, bought 140,000 shares at $7.32 on June 12, 2015. Following this transaction, the Chief Executive Officer owned 5.4 million shares meaning that the stake was boosted by 2.64% with the 140,000-share transaction.

The shares most recently traded at $7.58, up $0.26, or 3.48% since the insider transaction. Historical insider transactions for Prospect Capital Corporation go as follows:

  • 4-Week # shares bought: 216,060
  • 12-Week # shares bought: 248,060
  • 24-Week # shares bought: 249,060

The average volume for Prospect Capital Corporation has been 2.7 million shares per day over the past 30 days. Prospect Capital Corporation has a market cap of $2.7 billion and is part of the financial sector and financial services industry. Shares are down 9.44% year-to-date as of the close of trading on Friday.

Prospect Capital Corporation is a business development company. The stock currently has a dividend yield of 13.37%. The company has a P/E ratio of 7.6. Currently, there are 3 analysts who rate Prospect Capital Corporation a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PSEC - FREE

TheStreet Quant Ratings rates Prospect Capital Corporation as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Prospect Capital Corporation Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively